PTPRM — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13736685	1.00	2/20
SCHEMBL15829189	1.00	2/20
SCHEMBL18230879	0.81	2/20
SCHEMBL15829194	0.80	2/20
SCHEMBL15829188	0.78	2/20
SCHEMBL15829190	0.78	2/20
SCHEMBL15829193	0.77	2/20
SCHEMBL18230880	0.76	2/20
SCHEMBL15829191	0.75	2/20
SCHEMBL15829185	0.67	2/20
SCHEMBL18230877	0.67	2/20
SCHEMBL18231230	0.66	2/20
SCHEMBL15829192	0.65	2/20
SCHEMBL15829168	0.65	2/20
SCHEMBL15829166	0.62	2/20
SCHEMBL15829167	0.60	2/20
SCHEMBL15829187	0.59	2/20
SCHEMBL15829172	0.58	2/20
SCHEMBL15829183	0.57	2/20
SCHEMBL15829184	0.53	2/20

Clinical trials — most relevant to PTPRM by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
co Ihibtory Receptor in Preeclampsia	PHASE4	UNKNOWN
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	PHASE3	RECRUITING
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Ruxolitinib in Patients With Myelofibrosis	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Renal Transplantation	nan	RECRUITING
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPRM binder may also engage these)

Protein	Name	Similarity
P35822	—	1.000	P35822 →
Q99M80	—	1.000	Q99M80 →
Q15262	—	1.000	Q15262 →
B3DK56	—	1.000	B3DK56 →
O14522	—	1.000	O14522 →
Q92729	—	0.999	Q92729 →
P28828	—	0.999	P28828 →
Q6YI48	—	0.998	Q6YI48 →
P16620	—	0.997	P16620 →
P52583	—	0.997	P52583 →
O73798	—	0.996	O73798 →
O18016	—	0.996	O18016 →
Q2QLA9	—	0.996	Q2QLA9 →
B1AUH1	—	0.995	B1AUH1 →
Q09YK0	—	0.995	Q09YK0 →
Q00495	—	0.995	Q00495 →
TEK	Angiopoietin-1 receptor	0.995	landscape →
Q75ZY9	—	0.995	Q75ZY9 →
Q06807	—	0.995	Q06807 →
P04157	—	0.995	P04157 →
Q93105	—	0.995	Q93105 →
Q00PJ8	—	0.995	Q00PJ8 →
Q108U6	—	0.995	Q108U6 →
Q8AXC7	—	0.994	Q8AXC7 →
P43481	—	0.994	P43481 →
P54757	—	0.994	P54757 →
Q62413	—	0.994	Q62413 →
A1X150	—	0.994	A1X150 →
Q07DZ1	—	0.994	Q07DZ1 →
Q76II0	—	0.994	Q76II0 →